After a study linked semaglutide to blindness condition, experts warn about premature conclusions on causal association due to diabetes-related risks and need for further investigation.
Financial analysts express concerns about market implications but urge caution in interpreting study linking semaglutide to increased risk of blindness.
[
Collection
]
[
|
...
]